## **Pain: Current Pharmacologic Treatments**

#### First-line treatments

- Ongoing central neuropathic pain
  - Gabapentin and pregabalin
  - Antidepressants: SNRIs and TCAs
- Trigeminal neuralgia and other paroxysmal pain
  - Sodium channel blockers carbamazepine and oxcarbazepine
    - Poor tolerance due to side effects
- Based on research in general population and limited number of studies in MS population

### **Nabiximols and MS-Related Pain**

- Mixed results in studies of spasticity-related pain, central neuropathic pain, or overall pain experience, in patients with MS<sup>1</sup>
- American Academy of Neurology (AAN) summarized evidence as suggesting that nabiximols is "probably effective for treating MS-related pain or painful spasms"
  - AAN does not recommend the use of any cannabis products for neurologic conditions, except for FDA-approved cannabidiol for limited use in certain rare diseases<sup>3</sup>

# **Pain: Nonpharmacolog Treatment Options**

A recent meta-analysis of controlled trials identified multiple nonpharmacologic treatments significantly associated with reduced pain in MS population

#### **Mind-Body Therapies**

Cognitive behavioral therapy

**Hypnosis** 

Mindfulness-based interventions

### **Localized Therapies**

Transcranial direct current stimulation

Transcranial random noise stimulation

Reflexology

Massage